Table 2 The OS and DFS of breast cancer molecular subtypes in different stages of the disease
From: Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes
| Â | N | 5-Years outcome | ||||
|---|---|---|---|---|---|---|
Mortality rate N (%) | RR N (%) | DMR N (%) | OS | DFS | ||
All patients | 1287 | 134 (10.4) | 53 (4.1) | 82 (6.4) | 86.3 | 79.3 |
HR+/Her2+ | 261 | 30 (11.5) | 9 (3.4) | 23 (8.8) | 83.4 | 77.3 |
HR+/Her2− | 658 | 47 (7.1) | 17 (2.6) | 47 (7.1) | 90.2 | 84.2 |
HR−/Her2+ | 163 | 28 (17.2) | 17 (10.4) | 23 (14.1) | 77.8 | 62.3 |
HR−/Her2− | 205 | 29 (14.1) | 10 (4.9) | 19 (9.3) | 81.0 | 76.5 |
p-valuea |  |  |  |  |  < 0.001 |  < 0.001 |
Stage I | 195 | 3 (1.5) | 8 (4.1) | 6 (3.1) | 96.8 | 89.3 |
HR+/Her2+ | 31 | 2 (6.5) | 1 (3.2) | 2 (6.5) | 89.2Â + | 63.1 |
HR+/Her2− | 114 | 1 (0.9) | 2 (1.8) | 2 (1.8) | 97.0 | 93.8 |
HR−/Her2+ | 17 | 0 (0) | 3 (17.6) | 2 (11.8) | 90.0 | 47.7 |
HR−/Her2− | 33 | 0 (0) | 2 (6.1) | 0 (0) | 90.0 | 81.9 |
p-valuea | Â | Â | Â | Â | 0.064 | 0.004 |
Stage II | 681 | 56 (8.2) | 30 (4.4) | 55 (8.1) | 88.6 | 82.2 |
HR+/Her2+ | 135 | 11 (8.1) | 4 (3) | 11 (8.1) | 87.0 | 81.7 |
HR+/Her2− | 351 | 16 (4.6) | 11 (3.1) | 21 (6) | 92.8 | 87.3 |
HR−/Her2+ | 82 | 17 (20.7) | 9 (11) | 12 (14.6) | 71.1 | 57.4 |
HR−/Her2− | 113 | 12 (10.6) | 6 (5.3) | 11 (9.7) | 83.9 | 79.2 |
p-valuea |  |  |  |  |  < 0.001 |  < 0.001 |
Stage III | 411 | 75 (18.2) | 15 (3.6) | 51 (12.4) | 75.8 | 68.6 |
HR+/Her2+ | 95 | 17 (17.9) | 4 (4.2) | 10 (10.5) | 73.9 | 69.1 |
HR+/Her2− | 193 | 30 (15.5) | 4 (2.1) | 24 (12.4) | 78.3 | 70.9 |
HR−/Her2+ | 64 | 11 (17.2) | 5 (7.8) | 9 (14.1) | 76.7 | 62.0 |
HR−/Her2− | 59 | 17 (28.8) | 2 (3.4) | 8 (13.6) | 57.1 | 55.1 |
p-valuea | Â | Â | Â | Â | 0.078 | 0.130 |